Antimicrobial resistance (AMR) already causes more than 700,000 deaths globally per year.¹ Without action, this number could rise to 10 million by 2050 – more than current deaths from cancer.²

KNOWLEDGE IS POWER

Antimicrobial resistance is a serious threat to modern medicine and global health as we know it.^1–3

Bacteria, fungi, and viruses are changing. Pathogens are gaining resistance against treatments designed to kill them.^4,5 Overuse and misuse of antimicrobial medicines, climate change, increased international travel and trade, and sparse novel drug pipelines are all contributing to the problem.^4,5

We need to find ways to preserve the effectiveness of these medicines, and fast. 
Drug-resistant infections are tough – and sometimes impossible – to treat.⁴

Antimicrobial stewardship (AMS) promotes the responsible use of anti-infectives and is critical to addressing antimicrobial resistance,¹ but to work effectively it needs immediate and coordinated action.

JOIN THE FIGHT WITH PFIZER

For over 170 years, Pfizer has made significant contributions to improving health around the world, using science to create breakthroughs that help save patient’s lives.⁶ We're continuing our dedication to addressing evolving disease challenges and facing antimicrobial resistance head on.
 

Our comprehensive approach to stewardship ranges from education to research to patient engagement. We’re also the first pharmaceutical company to publicly share raw data through our antimicrobial surveillance website platform, the ATLAS (Antimicrobial Testing Leadership and Surveillance) database.⁷

As a result of our pioneering efforts, we have been recognized as the industry leader in antimicrobial stewardship in the Access to Medicine Foundation’s 2021 AMR Benchmark Report, which evaluates our industry’s progress in the fight against antimicrobial resistance.⁸

We also know the importance of a progressive clinical pipeline. Pfizer is one of the few large research-based pharmaceutical companies still active in R&D for anti-infectives.⁹ We continue to develop innovative treatments and vaccines, and solutions that go beyond medicine.

Even with one of the industry’s largest and most diverse portfolios of antimicrobials,⁹ we can’t fight this battle alone. Coming together as part of the broader infectious disease ecosystem is vital to the success of any stewardship initiative. 

The future of antimicrobials needs you.